Stuart Black - Concepedia

Author

Stuart Black

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Stuart Black

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)AGCO (United Kingdom)

About

Stuart Black is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.5K
2	Cell Biology	5	5	1.4K
3	Health Sciences	2	2	725
4	Engineering	1	1	64
5	Microbiology	1	1	64

Stuart Black

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors Erick J. Morris, Sharda Jha, Clifford R. Restaino, Cancer Discovery PharmacotherapyTumor BiologyDrug ResistanceMek InhibitorsReceptor Tyrosine Kinase	2013	673
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway Asra Mirza, Marnie McGuirk, Tish Hockenberry, Oncogene Tumor BiologyWild-type P53P53-dependent Apoptotic PathwayPathologyTumor Suppressor	2002	534
Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules Hena R. Ashar, Linda James, Kimberly Gray, Journal of Biological Chemistry	2000	320
Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors Terrill K. McClanahan, Sandra Koseoglu, Kathleen B. Smith, Cancer Biology & Therapy	2006	181
Transcriptional Regulation during p21/-induced Apoptosis in Human Ovarian Cancer Cells Qun Wu, Paul T. Kirschmeier, Tish Hockenberry, Journal of Biological Chemistry	2002	123
The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell Lines Hena R. Ashar, Linda James, Kimberly Gray, Experimental Cell Research Tumor BiologyG1 PauseOncogenic AgentMedicineCell Biology	2001	111
RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis Asra Mirza, Andrea Basso, Stuart Black, Cancer Biology & Therapy	2005	80
Use of the Escherichia coli ssb Gene to Prevent Bioreactor Takeover by Plasmidless Cells Ronald D. Porter, Stuart Black, Sachin Pannuri, Nature Biotechnology EngineeringMedicinePrevent Bioreactor TakeoverPlasmidless CellsBacteriology	1990	64
Dissecting Therapeutic Resistance to ERK Inhibition Sharda Jha, Erick J. Morris, Alan Hruza, Molecular Cancer Therapeutics Health SciencesNovel TherapyMedicineReceptor Tyrosine KinaseErk Inhibition	2016	52
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology Sobhana Babu Boga, Yongqi Deng, Liang Zhu, ACS Medicinal Chemistry Letters	2018	49

Page 1